

16th Winter Conference on Medicinal & Bioorganic Chemistry

January 29th - February 2nd 2023
Steamboat Springs Resort, Colorado

Organised in collaboration with:



Provisional Program



Sunday 29th January 2023

- 1.00 – 5.00pm** **Registration**
- 4.00 – 5.00** **Welcome Coffee and Cookies**
- 5.00** **Welcome and Opening Remarks – Philippe Nantermet, Conference Chair**
- Welcome to the 2023 MBCF Scholars – Maria Chiriac, Member of the Board**
- 5.20 – 7.40 pm** **Drug Hunting**
Chair: *Klemens Hoegenauer, Novartis*
- Kentaro Futatsugi**, Pfizer
Title to be confirmed
- Woody Sherman**, Roivant
Title to be confirmed
- Jason Shields**, AstraZeneca
Title to be confirmed
- Drug Hunter Award Introduction and Prize**
Chairs: *Philippe Nantermet and Matthew Hayward*
- Ian M. Bell**, Merck (**Drug Hunter Award**)
CGRP Receptor Antagonists for the Treatment of Migraine
- 7.40 – 10.00 pm** **Welcome Networking Reception in the Exhibition Area**

Monday 30th January 2023

7.00 – 8.00 am **Good Morning Buffet Breakfast**

8.00 - 11.00 am **Enabling Methodology and Technology**

Chair: Iulia Strambeanu, Janssen

David Leitch, University of Victoria

Mapping Chemical Space via High-throughput Experimentation: New Tools, New Reactions, and New Bicyclic Scaffolds

Song Lin, Cornell

New Strategies for Redox Catalysis

Amanda Dombrowski, AbbVie

Enabling and Accelerating Drug Discovery with High Throughput Chemistry

Liana Allen, Vertex

Impact of High Throughput Experimentation in Medicinal Chemistry at Vertex; from Microscale to Multigram

Kohki Nakafuku, Janssen

Discovery of Small Molecule Inhibitors Using a Modern Screening Paradigm and High Throughput Chemistry

4.00 - 5.00 pm **Back from the Slopes – Coffee and Cookie Break**

5.00 – 8.00 pm **Antivirals and Pandemic Diseases, Past, Present and Future**

Chair: John McCauley (Merck)

Jamie Tuttle, Pfizer

Title to be confirmed

Patrick Fier, Merck

Title to be confirmed

Phil Sanderson, NIH

Title to be confirmed

Uwe Schoenbeck, Pfizer Inc.

Title to be confirmed

Tuesday 31st January 2023

7.00 – 8.00 am Good Morning Buffet Breakfast

8.00 – 11.00 am SynthChemBio
Chair: *Niyi Fadeyi, InduPro*

Christopher am Ende, Pfizer Inc.
Title to be confirmed

Emma Grant, GlaxoSmithKline
Reactive Fragments in Covalent Drug Discovery

Rob Oslund, InduPro Therapeutics
Title to be confirmed

Francisco Garcia, Novartis Institutes for Biomedical Research
Title to be confirmed

4.00 - 5.00 pm Back from the Slopes – Coffee and Cookie Break

5.00 – 6.40 pm General Session: Synthesis and Med Chem
Chair: *Amy Dounay, Colorado College*

Speaker Selected from Abstracts, Affiliation
Title to be confirmed

Speaker Selected from Abstracts, Affiliation
Title to be confirmed

Speaker Selected from Abstracts, Affiliation
Title to be confirmed

Speaker Selected from Abstracts, Affiliation
Title to be confirmed

Speaker Selected from Abstracts, Affiliation
Title to be confirmed

6.40 – 8.00 pm Networking Session
Drinks & Poster Session

Wednesday 1st February 2023

7.00 – 8.00 am Good Morning Buffet Breakfast

8.00 – 11.00 am Beyond Ro5 and Novel Modalities
Chair: *Lou Chupak, Bristol Myers Squibb*

Dave Degoey, AbbVie
Title to be confirmed

Patrizio Mattei, Roche
Title to be confirmed

4.00 - 5.00 pm Back from the Slopes – Coffee and Cookie Break

5.00 – 8.00 pm MacMillan Alumni Session: Topics in Medicinal and Synthetic Chemistry
Chair: *Michael VanHeyest, GSK*

Raphaelle Berger, Merck
Discovery of MK-6158 an oral, once daily, Soluble Guanylate Cyclase (sGC) Stimulator for the treatment of Pulmonary Arterial Hypertension

Andrew Capacci, Biogen
The Development of Asymmetric Organocatalysis and Metallaphotoredox

Vy Dong, UCI
Choose Your Own Adventure in Metal-Hydride Catalysis

Robert M. Williams' Memorial KEYNOTE LECTURE
Program Chair: **Mike VanHeyest, GSK**

2021 Nobel Laureate David W.C. MacMillan Princeton University
The Development of Asymmetric Organocatalysis and Metallaphotoredox

Thursday 2nd February 2023

7.00 – 8.00 am **Good Morning buffet breakfast**

8.00 – 11.00 am **Late Breaking Stories and 1st Disclosures**
Chair: *Rebecca Gallego, Pfizer*

Rob Kania, Kinnate
Title to be confirmed

Manuel Ruiz, Merck
Potent Dual Plasmeprin IX/X Inhibitors towards the Treatment of Malaria

Nicolas Soldermann, Novartis
Title to be confirmed

5.00 pm **Top of the Gondola**

Networking Session
Pre-Dinner Drinks

Conference Dinner

Conference Closes